<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202614</url>
  </required_header>
  <id_info>
    <org_study_id>PET-TC Adenocarcinoma</org_study_id>
    <nct_id>NCT04202614</nct_id>
  </id_info>
  <brief_title>Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung Adenocarcinoma</brief_title>
  <official_title>Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical and derived data from the preoperative computed axial tomography (CT) and
      Positron Emission Tomography (PET) of patients with pathological stage I pulmonary
      adenocarcinoma will be analyzed retrospectively, classified according to the current
      pathological classification IASLC / ATS / ERS of pulmonary adenocarcinoma, subjected to
      surgical treatment in our Operating Unit between August 2006 and July 2011. A follow-up will
      be performed on the patients enrolled in the study up to the date of death, and in any case
      no later than October 31, 2019
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stratification of stage I adenocarcinoma patients, using clinical data derived from preoperative CT and PET</measure>
    <time_frame>12 months</time_frame>
    <description>classify patients with pulmonary adenocarcinoma in stage I (retrospective cases) based on the current pathological classification IASLC / ATS / ERS of pulmonary adenocarcinoma using clinical data and derived from preoperative CT and PET</description>
  </primary_outcome>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Stage I Pulmonary Adenocarcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from pulmonary adenocarcinoma in stage I
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients suffering from pulmonary adenocarcinoma in stage I underwent CT, PET and
             surgical treatment with radical intent, at San Raffale Hospital (thoracic surgery)
             between August 2006 and July 2011

        Exclusion Criteria:

          -  primary pulmonary neoplasms other than adenocarcinoma; locally advanced or metastatic
             disease stage; non-radical resection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Angelo Carretta, MD</last_name>
    <phone>+39022643</phone>
    <phone_ext>7139</phone_ext>
    <email>carretta.angelo@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Piergiorgio Muriana, MD</last_name>
    <phone>+39022643</phone>
    <phone_ext>7139</phone_ext>
    <email>piergiorgio.muriana@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Carretta, MD</last_name>
      <phone>+39022643</phone>
      <phone_ext>7139</phone_ext>
      <email>carretta.angelo@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Piergiorgio Muriana, MD</last_name>
      <phone>+39022643</phone>
      <phone_ext>7139</phone_ext>
      <email>piergiorgio.muriana@hsr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Khullar OV, Liu Y, Gillespie T, Higgins KA, Ramalingam S, Lipscomb J, Fernandez FG. Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. J Thorac Oncol. 2015 Nov;10(11):1625-33. doi: 10.1097/JTO.0000000000000664.</citation>
    <PMID>26352534</PMID>
  </reference>
  <results_reference>
    <citation>Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630.</citation>
    <PMID>26291008</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsutani Y, Miyata Y, Nakayama H, Okumura S, Adachi S, Yoshimura M, Okada M. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy. Chest. 2014 Jan;145(1):66-71. doi: 10.1378/chest.13-1094.</citation>
    <PMID>24551879</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Prof. Carretta Angelo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

